Anti-IgE therapy for allergic bronchopulmonary aspergillosis.
J Microbiol Immunol Infect
; 49(3): 459-63, 2016 Jun.
Article
em En
| MEDLINE
| ID: mdl-24291616
ABSTRACT
Allergic bronchopulmonary aspergillosis (ABPA) is a severe type of asthma. Some cases are resistant to treatment, even with regular use of antiasthmatic drugs and antifungal agents. The diagnosis of ABPA was made in a 40-year-old patient with ABPA according to the Rosenberg-Patterson criteria. Symptoms were not controlled despite regular use of antiasthmatic drugs, daily systemic steroids, and antifungal agents. Omalizumab, administered in an attempt to stabilize these uncontrolled symptoms, was effective with no adverse events. Our experience suggests omalizumab is a potential candidate drug for controlling steroid-dependent ABPA.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Aspergilose Broncopulmonar Alérgica
/
Anticorpos Anti-Idiotípicos
/
Antiasmáticos
/
Omalizumab
/
Imunoterapia
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article